Abstract
Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Recent Patents on Anti-Cancer Drug Discovery
Title:Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Volume: 8 Issue: 2
Author(s): Riccardo Petrelli, Patrizia Vita, Ilaria Torquati, Krzysztof Felczak, Daniel J. Wilson, Palmarisa Franchetti and Loredana Cappellacci
Affiliation:
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Abstract: Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Export Options
About this article
Cite this article as:
Petrelli Riccardo, Vita Patrizia, Torquati Ilaria, Felczak Krzysztof, J. Wilson Daniel, Franchetti Palmarisa and Cappellacci Loredana, Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020001
DOI https://dx.doi.org/10.2174/1574892811308020001 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Toxicity and Surface Modification of Dendrimers: A Critical Review
Current Drug Delivery Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal Synthetic and Biological Attributes of Pyrimidine Derivatives: A Recent Update
Current Organic Synthesis Kaempferol-3-<i>O</i>-Rhamnoside Inhibits the Proliferation of Jurkat Cells Through Jun Amino-Terminal Kinase Signaling
The Natural Products Journal Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Clinical Pharmacogenomics of Thiopurine S-methyltransferase
Current Clinical Pharmacology Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism A Discussion of MicroRNAs in Cancers
Current Bioinformatics Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry